Turnstone Biologics Corp. (TSBX) Stock Analysis & Investment Frameworks
Turnstone Biologics Corp. (TSBX) stock analysis on Invetso. Review Turnstone Biologics Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Turnstone Biologics Corp. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Turnstone Biologics Corp. Key Financial Metrics
- Market Cap: $8.21M
- Revenue: $N/A
- ROE: -108.87%
- ROIC: -219.51%
- Dividend Yield: N/A
About Turnstone Biologics Corp.
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.